0

Mouse Models of Thyroid Cancer: Bridging Pathogenesis and Novel Therapeutics

Yuchen Jin, Min Liu, Ri Sa, Hao Fu, Lin Cheng, Libo Chen

Cancer Lett. 2020 Jan 28;469:35-53.

PMID: 31589905

Abstract:

Due to a global increase in the incidence of thyroid cancer, numerous novel mouse models were established to reveal thyroid cancer pathogenesis and test promising therapeutic strategies, necessitating a comprehensive review of translational medicine that covers (i) the role of mouse models in the research of thyroid cancer pathogenesis, and (ii) preclinical testing of potential anti-thyroid cancer therapeutics. The present review article aims to: (i) describe the current approaches for mouse modeling of thyroid cancer, (ii) provide insight into the biology and genetics of thyroid cancers, and (iii) offer guidance on the use of mouse models for testing potential therapeutics in preclinical settings. Based on research with mouse models of thyroid cancer pathogenesis involving the RTK, RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, SRC, and JAK-STAT signaling pathways, inhibitors of VEGFR, MEK, mTOR, SRC, and STAT3 have been developed as anti-thyroid cancer drugs for "bench-to-bedside" translation. In the future, mouse models of thyroid cancer will be designed to be ''humanized" and "patient-like," offering opportunities to: (i) investigate the pathogenesis of thyroid cancer through target screening based on the CRISPR/Cas system, (ii) test drugs based on new mouse models, and (iii) explore the underlying mechanisms based on multi-omics.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP331656929 ERK Inhibitor III - CAS 331656-92-9 ERK Inhibitor III - CAS 331656-92-9 331656-92-9 Price
AP457081037-B JAK Inhibitor I - CAS 457081-03-7 JAK Inhibitor I - CAS 457081-03-7 457081-03-7 Price
qrcode